ANTENGENE-B (06996) announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for the CLINCH-2 study. This Phase IB/II trial will evaluate ATG-022 (a CLDN18.2-targeting antibody-drug conjugate ADC) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as well as ATG-022 combined with pembrolizumab and chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.